SECTION I · THE BRIEF
Brief #04840Updated 22 SEP 2026REMOTEGreenhouseMEDICAL ORGANIZATIONS
Employbl Company Profile

Manager, Investor Relations and Corporate Communications

Iovance Biotherapeutics is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.

Location
Remote
Company size
838–838
Posted
Today
Via
Greenhouse
Section II · Full ProfileFree with an account
  • 01Comp band & equity packageLocked
  • 02Seniority & experience requirementsLocked
  • 03Interview process & rubricLocked
  • 04Hiring manager & team contextLocked
  • 05Growth trajectory in this roleLocked
  • 06Offer & decision timelineLocked

Free account · no card · 2 minutes

Manager, Investor Relations and Corporate Communications

Iovance Biotherapeutics· RemoteView company profile


Job title
Manager, Investor Relations and Corporate Communications
Job location
Remote
Job description

AboutIovance Biotherapeutics, Inc. 

Iovance Biotherapeutics, Inc.  is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit www.iovance.com

Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. 

Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com

Overview

The Manager, Investor Relations and Corporate Communications, will help drive high-impact communications across investors, media, employees, and other key stakeholders. Reporting to the Senior Director, Corporate Communications, and partnering closely with the Investor Relations and Corporate Communications team, this role will turn company strategy, milestones, and data into clear, compelling communications that support investor engagement, corporate visibility, and internal alignment.

This is a hands-on, execution-oriented role for a strong communicator who thrives in a fast-moving public company environment. The ideal candidate brings curiosity, financial acumen, strong project management skills, and the ability to move quickly from insight to action while supporting executive communications, investor engagement, and commercial-stage biotechnology operations.

Essential Functions and Responsibilities

  • Investor Relations & Corporate Communications 
  • Create and maintain high-impact investor relations and corporate communications materials, including press releases, earnings scripts, Q&A documents, corporate presentations, FAQs, fact sheets, executive biographies, website content, investor decks, templates, and social media content. 
  • Drive internal reviews, approvals, and final deliverables on behalf of the IR and corporate communications team. 
  • Support analyst and institutional investor engagement and help advance investor targeting strategies. 
  • Monitor metrics and analytics for multi-channel external engagement, media coverage, share of voice, company reputation, market activity, analyst sentiment, peer performance, and consensus estimates, to deliver real-time insights for leadership. 
  • Translate key milestones, including earnings, financings, clinical updates, and business developments, into timely, consistent communications for employees, investors, media, and other stakeholders. 
  • Own logistics, timelines, briefing materials, and execution support for events led by the team, including internal town halls, media interviews/roundtables and investor days. 
  • Support media relations by preparing press materials, tracking coverage, and helping build productive relationships with traditional and social media outlets. 
  • Manage agencies and vendors to keep projects moving, on budget, and aligned with investor relations and corporate communications priorities. 
  • Cross-Functional & Operational 
  • Partner with Finance, Legal, Commercial, R&D, Patient Advocacy, and other teams to deliver accurate, consistent, and compliant communications across filings, disclosures, investor materials, the corporate website, internal meetings, and social media. 
  • Improve processes, tools, and workflows to increase the speed, organization, and scalability of the investor relations and corporate communications function. 
  • Lead or support priority investor relations and communications projects as business needs evolve. 
  • Must adhere to Iovance Biotherapeutics’ core values, policies, procedures, and business ethics.
  • Perform miscellaneous duties as assigned. 

Required Education, Skills, and Knowledge 

  • 8+ years of experience in investor relations, external and internal corporate communications, public relations, equity research, investment banking, corporate finance, healthcare communications, or related fields. 
  • Bachelor’s degree required, preferably in Communications, Public Relations, Journalism, Business, Finance, Marketing, Life Sciences, or a related field.
  • Experience within biotechnology, pharmaceutical, healthcare, agency, or public company environments strongly preferred. 
  • Working knowledge of capital markets, valuation, investor behavior, sell-side research, SEC disclosure requirements, Regulation FD, and public company investor relations practices. 
  • Strong financial and analytical skills, with the ability to turn clinical, scientific, and financial information into clear investment messaging. 
  • Excellent writer and communicator with experience developing persuasive scripts, presentations, executive materials, and stakeholder communications. 
  • Highly organized project manager who can manage multiple priorities, timelines, and stakeholders with speed, accuracy, and attention to detail. 
  • Strong relationship builder with executive presence, sound judgment, and the ability to influence without authority. 
  • Advanced proficiency in PowerPoint, Excel, Outlook, OneDrive, and SharePoint; experience with FactSet, Bloomberg, HubSpot, WordPress, or market-monitoring platforms is a plus. 
  • Professional maturity, discretion, and sound judgment in handling confidential information. 
  • Proactive self-starter who takes ownership, solves problems, and moves work forward with urgency and curiosity. 

Physical Demands and Activities Required

The physical demands described here represent those an employee may encounter while performing the essential functions of this job. Reasonable accommodation may be provided to enable individuals to perform these functions.

  • Ability to remain in a stationary position for extended periods
  • Ability to move about within an office or remote workspace and exert up to 10 pounds of force occasionally
  • Visual acuity sufficient for preparing and analyzing data, viewing computer screens, and extensive reading
  • Repetitive motion involving wrists, hands, and/or fingers
  • Ability to communicate effectively to exchange information
  • Cognitive: Ability to engage in analytical, conceptual, and problem‑solving activities in a dynamic business environment

Work Environment

This role operates in a professional office or remote work environment and requires routine use of standard office equipment and technology. Employees working remotely are expected to maintain a safe workspace free from recognized hazards.

#LI-Remote

The annual base salary we reasonably expect to pay is listed. Individual pay decisions depend on various factors, such as primary work location, complexity and responsibility of the role, job duties/requirements, and relevant education, experience and skills. 

Pay Transparency
$140,000$160,000 USD

The statements contained in this document are intended to describe the general nature and level of work being performed by a colleague assigned to this description. They are not intended to constitute a comprehensive list of functions, duties, or local variances. Management retains the discretion to add or to change the duties of the position at any time.

Iovance is committed to cultivating and offering a diverse and inclusive work environment. As an equal-opportunity employer, our employees and applicants will be considered without regard to an individual’s race, color, religion, sex, pregnancy, national origin, age, physical and mental disability, marital status, sexual orientation, gender identity, gender expression, genetic information, military and veteran status, and any other characteristic protected by applicable law. If you need assistance or accommodation to apply to one of our opportunities, please contact careers@iovance.com.  

By voluntarily providing information and clicking “Submit Application”, you explicitly consent to the collection and use of your personal information for the purposes described above and in our Candidate Privacy Notice


View job listing ↗
The Saturday Briefing

Get the Saturday tech briefing

New company profiles, funding moves, and who’s hiring across the market — every Saturday morning.

Iovance Biotherapeutics headquarters

San Carlos, CA

Company size

838838 employees

Founded

2007

Total raised

$1,576,400,128

View company profile ↗

Funding rounds

  • Post Ipo Equity$211M
  • Post Ipo Equity$150M
  • Post Ipo Equity$603.7M
  • Post Ipo Equity$252.2M
  • Post Ipo Equity$172.5M
  • Post Ipo Equity$100M

    Quogue Capital, OrbiMed Advisors, Frazier Management, Broadfin Capital

  • Post Ipo Equity$64M
  • Post Ipo Equity$23M
  • IPOUndisclosed